Delving into the Latest Updates on Lamivudine/Raltegravir Potassium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DUTREBIS, Lamivudine/raltegravir, Raltegravir/3TC

+ [3]

Target

HIV integrase x RT

Mechanism

HIV-1 integrase inhibitors(HIV integrase inhibitors), RT inhibitors(Reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization-

Inactive Organization

Merck Sharp & Dohme Corp.

Drug Highest PhaseWithdrawn

First Approval Date

US (06 Feb 2015),

HIV Infections

Regulation-

Login to view timeline

Structure

Molecular FormulaC20H21FKN6O5

InChIKeyNLDVPINGTPMESH-UHFFFAOYSA-N

CAS Registry871038-72-1

View All Structures (2)

Raltegravir and lamivudine have been part of highly active therapy regimens throughout the past years of antiretroviral therapy. A fixed-dose, single-tablet regimen comprising a non-poloxamer formulation of the integrase inhibitor raltegravir and the transcriptase inhibitor lamivudine (raltegravir/lamivudine; Dutrebis(®)) has been recently licensed for the treatment of HIV-1 infection. In several Phase I pharmacokinetic studies, one Dutrebis (150 mg lamivudine/300 mg raltegravir) fixed-dose combination tablet showed a higher bioavailability but comparable lamivudine and 400 mg raltegravir poloxamer exposures. Thus, the co-administration of raltegravir together with lamivudine created a potent, effective, well-tolerated antiretroviral combination, which could be more convenient for the patient. However, the disadvantage of twice a day administration, and the existence of other fixed-dose combinations limit its widespread clinical use. This article reviews pharmacokinetics data and appraises their potential use in current and future HIV therapy.

100 Deals associated with Lamivudine/Raltegravir Potassium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lamivudine/Raltegravir Potassium	J05AR16	-

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


VISEND (IAS2020)	Not Applicable	-	-	Tenofovir-disoproxil-fumarate, Lamivudine and Dolutegravir (TLD)	hxrdqfwiwi(lemdtzoshb) = rjznxjpmss wqxsoxzwpv (hhxxaxwxgm, (179)) View more	-	01 Jan 2020
				Tenofovir-alafenamide, Emtricitabine and Dolutegravir (TAFED)	hxrdqfwiwi(lemdtzoshb) = tytfjkuyuu wqxsoxzwpv (hhxxaxwxgm, (449)) View more
IAS2013	Not Applicable	-	-	3TC/NVP/AZT dispersible tablet	mnwkadrwdc(hlobotveyg) = ztblfemkvq apijwoyfyr (kwvfxiigmq )	-	01 Jan 2013
IAS2007	Not Applicable	HIV Infections	-	3TC/ZDV/NVP	reonoqmtlz(vsghxwctcq) = dmwkxmeyhm iatmdnwtki (mleedbaeia )	-	01 Jan 2007
IAS2007	Not Applicable	Maintenance	155	LPV/r+ZDV/3TC induction followed by LPV/r monotherapy	(rbbzitmplz) = hmmmhbhjut zxdobrbllk (igeesvjxpj )	-	01 Jan 2007
				EFV+ZDV/3TC	(rbbzitmplz) = zoeivxnruy zxdobrbllk (igeesvjxpj )
IAS2006	Not Applicable	-	96	BID abacavir (ABC) + lamivudine (3TC)	sellyhgbfl(yaoazzkzlw) = rdngbypakk shtkwwefbw (zfueolevsh ) View more	-	01 Jan 2006
				QD ABC/3TC fixed dose combination (FDC)	sellyhgbfl(yaoazzkzlw) = gpeiqctblu shtkwwefbw (zfueolevsh ) View more
KLEAN Study (IAS2005)	Not Applicable	Hypersensitivity	887	ABC/3TC FDC plus a boosted PI	mndjxyewbm(hnbiuyttyl) = Cases of suspected ABC HSR were reported in 52 subjects (5.9%) completing > 6 weeks of therapy. Eight (0.9%) cases were considered mild (Grade 1), 24 (2.7%) were moderate (Grade 2), 18 (2.0%) were severe (Grade 3 or 4) and 2 cases had missing severity data. Twelve cases were hospitalized; no cases were fatal. Median time to onset of ABC HSR was 8 days (range: 0 - 35 days). yvogqotluh (udijoxhfgf )	-	01 Jan 2005
IAS2001	Not Applicable	-	-	ABC/3TC/APV	fmqbmqexis(nhwgowdpfb) = one subject withdrew due to GI symptoms attributed to APV (prior to RTV switch) wndiddbgan (grzqfgfyic ) View more	-	01 Jan 2001
				ABC/3TC/APV+RTV